PetVivo to Exhibit Spryng Technology at the American College of Veterinary Surgeons Surgery Summit October 24-26, 2024

John (OTCQB:PETV, PETVW)

MINNEAPOLIS, MN, UNITED STATES, October 14, 2024 /EINPresswire.com/ -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will exhibit at the American College of Veterinary Surgeons (“ACVS”) Surgery Summit to be held October 23rd to October 26th, 2024 at the Phoenix Convention Center in Phoenix, Arizona.

PetVivo will exhibit its lead product, Spryng ™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

“We are incredibly excited to participate in this year’s ACVS Surgery Summit. The ACVS provides us an excellent opportunity to demonstrate to leading veterinarian surgeons our innovative medical device for the management of osteoarthritis, Spryng with OsteoCushion Technology,” said PetVivo CEO, John Lai. “We welcome the opportunity to support ACVS and participate in this summit to explain the advantages of Spryng including the beneficial results we have witnessed when administered to horses and companion animals throughout the U.S.”

Visitors to the ACVS Surgery Summit can see the Spryng exhibit at booth #814 on October 24, 2024, 9:00 a.m. to 7:30 p.m., as well as on October 25, 9:00 a.m. to 5:00 p.m. and October 26, 9:00 a.m. to 2:00 p.m.

For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.

About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.

Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.

Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

John Lai
Petvivo Holdings, Inc.
+1 (952) 405-6216
email us here